Dengue Virus Capsid Protein Usurps Lipid Droplets for Viral Particle Formation

Dengue virus is responsible for the highest rates of disease and mortality among the members of the Flavivirus genus. Dengue epidemics are still occurring around the world, indicating an urgent need of prophylactic vaccines and antivirals. In recent years, a great deal has been learned about the mechanisms of dengue virus genome amplification. However, little is known about the process by which the capsid protein recruits the viral genome during encapsidation. Here, we found that the mature capsid protein in the cytoplasm of dengue virus infected cells accumulates on the surface of ER-derived organelles named lipid droplets. Mutagenesis analysis using infectious dengue virus clones has identified specific hydrophobic amino acids, located in the center of the capsid protein, as key elements for lipid droplet association. Substitutions of amino acid L50 or L54 in the capsid protein disrupted lipid droplet targeting and impaired viral particle formation. We also report that dengue virus infection increases the number of lipid droplets per cell, suggesting a link between lipid droplet metabolism and viral replication. In this regard, we found that pharmacological manipulation of the amount of lipid droplets in the cell can be a means to control dengue virus replication. In addition, we developed a novel genetic system to dissociate cis-acting RNA replication elements from the capsid coding sequence. Using this system, we found that mislocalization of a mutated capsid protein decreased viral RNA amplification. We propose that lipid droplets play multiple roles during the viral life cycle; they could sequester the viral capsid protein early during infection and provide a scaffold for genome encapsidation

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

RNA Sequences and Structures Required for the Recruitment and Activity of the Dengue Virus Polymerase*

Dengue virus RNA-dependent RNA polymerase specifically binds to the viral genome by interacting with a promoter element known as stem-loop A (SLA). Although a great deal has been learned in recent years about the function of this promoter in dengue virus-infected cells, the molecular details that explain how the SLA interacts with the polymerase to promote viral RNA synthesis remain poorly understood. Using RNA binding and polymerase activity assays, we defined two elements of the SLA that are involved in polymerase interaction and RNA synthesis. Mutations at the top of the SLA resulted in RNAs that retained the ability to bind the polymerase but impaired promoter-dependent RNA synthesis. These results indicate that protein binding to the SLA is not sufficient to induce polymerase activity and that specific nucleotides of the SLA are necessary to render an active polymerase-promoter complex for RNA synthesis. We also report that protein binding to the viral RNA induces conformational changes downstream of the promoter element. Furthermore, we found that structured RNA elements at the 3′ end of the template repress dengue virus polymerase activity in the context of a fully active SLA promoter. Using assays to evaluate initiation of RNA synthesis at the viral 3′-UTR, we found that the RNA-RNA interaction mediated by 5′-3′-hybridization was able to release the silencing effect of the 3′-stem-loop structure. We propose that the long range RNA-RNA interactions in the viral genome play multiple roles during RNA synthesis. Together, we provide new molecular details about the promoter-dependent dengue virus RNA polymerase activity

Biochemical properties of recombinant C protein with substitution L50S–L54S.

<p>A. High expression levels and dimerization of C_WT and C_L50S–L54S. SDS-PAGE stained with coomassie blue showing similar expression levels of the recombinant proteins. The molecular mass obtained by size exclusion chromatography (SEC) and light scattering for both proteins are indicated. B. Interaction of C_WT and C_L50S–L54S with the DENV 5′UTR RNA probe monitored by filter binding assay. Uniformly ³²P labeled RNA (0.1 nM) was incubated with increasing concentrations of the respective C protein. Bound indicates RNA-protein complexes retained in the nitrocellulose membrane and free denotes the unbound probes retained in the nylon membrane. The RNA probes bound and free in each membrane were visualized by PhosphoImaging. C. Quantification of the percentage of RNA probe bound was plotted as a function of C concentration and fitted using equation 1 (see <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1000632#s4" target="_blank">Materials and methods</a>). The dissociation constants K<i>ds</i> are indicated inside the plot.</p

Sequence of oligonucleotides.

<p>Sequence of oligonucleotides.</p

DENV infected cells accumulate the C protein around lipid droplets.

<p>A. Nuclear and cytoplasmic distribution of C protein in DENV infected BHK cells. Cells were infected with DENV2 and analyzed by immunofluorescence using a polyclonal anti-C antibody. Cells were fixed with methanol (MeOH) or paraformaldehyde (PFA) as indicated on the top. B. The C protein is targeted to lipid droplets. BHK, HepG2, and C6/36 cells were infected with DENV2, fixed at 48 h post-infection, probed with anti-C antibodies and BODIPY for lipid droplets staining, and examined by confocal microscopy. C. Subcellular fractionation of LDs. DENV-infected cell lysates were fractionated into lipid droplets (LD), cytosol (C), and microsome (M) fractions by sucrose gradient centrifugation. A total cytoplasmic extract was also included (T). The samples were immunoblotted with anti-ADRP and anti-C antibodies. D. Co-localization of C and ADRP on LDs. DENV infected BHK cells were analyzed by immunofluorescence with anti-ADRP and anti-C antibodies, and stained with BODIPY. E. DENV infection increases the number of lipid droplets. The amount of lipid droplets in control or DENV infected BHK cells were determined. Cells were fixed 48 h post- infection, incubated in 1.5% of OsO₄, and lipid bodies were enumerated by light microscopy in 50 consecutive cells in each slide in triplicates. The bars indicate the standard error of the mean (+/−SEM), (P<0.0002). F. Expression of C protein increases the number of lipid droplets. The amount of lipid droplets in control or C expressing BHK cells were determined as described above. The bars represent the standard error of the mean (P<0.0001).</p

Pharmacological inhibition of lipid droplets accumulation impairs DENV replication.

<p>A. Effect of C75 on the amount of lipid droplets in BHK cells. The amount of lipid droplets was quantified in BHK cells treated with different concentrations of C75. Control or DENV infected BHK cells were used. B. Inhibition of DENV replication in cells treated with C75. The amount of infectious viral particles produced at 24 and 48 h post-infection in BHK cells were evaluated by plaque assays in control or C75 treated cells as indicated. Error bars indicate the SD of three independent experiments. C. Effect of C75 on each step of the replication of the mDV-R. Viral stocks of the reporter mDV-R were used to infect BHK cells in the presence and absence C75. Luciferase activity was evaluated at 10 h post-infection to evaluate entry and translation (left panel), and at 24 and 48 h to evaluate RNA synthesis (right panel). D. The production of infectious viral particles produced in the experiment described in C was evaluated by infecting fresh BHK cells in the absence of the inhibitor, and assessing the luciferase activity 48 h after infection.</p

A new reporter virus that allows dissociation of cis-acting RNA elements from the capsid coding region confirms a role of L50 and L54 in DENV particle formation.

<p>A. Construction of a novel monocistronic DENV reporter system. At the top, schematic representation of the cis-acting replication elements located at the 5′ end of the DENV genome. The promoter stem-loop A (SLA), the cyclization sequence upstream of the AUG (5′UAR), the replication element cHP, and the cyclization sequence 5′CS are indicated. In the middle, the corresponding region of DENV polyprotein is shown. At the bottom, a schematic representation of the monocistronic DENV reporter construct (mDV-R) showing the duplication of the cis-acting elements (CAE) and the location of the luciferase and the viral proteins. B. Translation and replication of mutant mDV-R RNAs. BHK cells were transfected with DENV RNAs corresponding to the mDV-R WT, Mut ΔC with the complete deletion of C coding sequence, Mut α2.1, Mut α2.2, Mut α2, and Mut NS5, which carries a mutation in the catalytic GDD motif of the viral polymerase. Luciferase activity was measured as a function of time for each RNA as indicated at the bottom. C. Mutations in the α2 helix of the C protein impair viral particle formation. The media of the transfected cells from the experiment shown in B was collected at the indicated times and used to infect fresh cells. Luciferase activity was measured 48 h post-infection for each virus as indicated at the bottom. D. A matured form of C_L50SL54S protein expressed in BHK cells decreased the levels of DENV RNA synthesis. Immunofluorescence of BHK cells expressing the DENV C_WT or C_L50SL54S probed with anti C (green) and stained with Bodipy (red) for lipid droplets are shown in the right panel. The cells transfected with DV-R RNA WT were used to measure luciferase activity as a function of time, as indicated in the left panel.</p

The C protein contains the structural determinants for LD targeting.

<p>A. Schematic representation of the topology of the viral C and prM proteins on the ER membrane. The anchor peptide and the cleavage sites of the signal peptidase and viral NS3/2B proteases are indicated. The location of the FMDV2A protease replacing the NS3/2B site is shown in the scheme on the right. The western blot shows expression of the C protein in cytoplasmic extracts of cells transfected with a full length DENV RNA WT (Cwt) or the RNA including the FMDV2A site (C2A). B. The anchor peptide is dispensable for C accumulation on LDs. BHK cells transfected with the DENV-FMDV2A RNA were fixed and probed with antibodies against C and BODIPY to stain neutral lipids in LDs, as indicated on the top. C. Expression of the mature C protein in the absence of other viral components is sufficient for LD targeting. BHK cells were transfected with an expression plasmid that encode the mature form of DENV C protein. Twenty four h post-transfection cells were fixed and probed with anti-C antibodies followed by staining of lipid droplet.</p